Press release
HER2 Negative Metastatic Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive HER2 Negative Metastatic Breast Cancer Pipeline Report to explore emerging therapies, key HER2 Negative Metastatic Breast Cancer Companies, and future HER2 Negative Metastatic Breast Cancer treatment landscapes @ HER2 Negative Metastatic Breast Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the HER2 Negative Metastatic Breast Cancer Pipeline Report
* In February 2025:- Washington University School of Medicine:- This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
* In February 2025:- Stemline Therapeutics Inc.:- The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) advanced/metastatic breast cancer who received no prior cyclin-dependent kinase targeting enzymes CDK4 and CDK6 inhibitor (CDK4/6i) in the metastatic setting.
* In February 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.
* In February 2025:- Puma Biotechnology Inc.:- PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.
* In February 2025:- GE Healthcare:- This is a multi-center study in France to evaluate the impact of ESTROTEP PET/CT results on the therapeutic management of patients with metastatic breast cancer (MBC). Each patient will be screened to determine whether the patient meets all the inclusion criteria and none of the exclusion criteria.
* DelveInsight's HER2 Negative Metastatic Breast Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for HER2 Negative Metastatic Breast Cancer treatment.
* The leading HER2 Negative Metastatic Breast Cancer Companies such as BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc., AstraZeneca, Dantari, Inc ., and others.
* Promising HER2 Negative Metastatic Breast Cancer Therapies such as ADI-PEG 20, DAN-222, Niraparib, Cetuximab, BGB-290, and others.
Discover how the HER2 Negative Metastatic Breast Cancer treatment paradigm is evolving. Access DelveInsight's in-depth HER2 Negative Metastatic Breast Cancer Pipeline Analysis for a closer look at promising breakthroughs @ HER2 Negative Metastatic Breast Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HER2 Negative Metastatic Breast Cancer Emerging Drugs Profile
* Pamiparib: BeiGene
Pamiparib is a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2 enzymes that is being evaluated as a potential monotherapy and in combinations for the treatment of various solid tumors. It is believed that pamiparib has the potential to be differentiated from other PARP inhibitors because of its brain penetration, greater selectivity, strong DNA-trapping activity, and good oral bioavailability demonstrated in preclinical models. . Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Her2 Negative Metastatic Breast Cancers.
* Onapristone: Context Therapeutics
ONA-XR is an investigational medicine that prevents progesterone signaling by blocking the interaction between progesterone and its binding partner, progesterone receptor. Onapristone is the only known full PR antagonist. Currently, there are no approved therapies that selectively target progesterone receptor positive (PR+) cancers. Preclinical and clinical data suggest that onapristone extended release (ONA-XR) has anticancer activity by inhibiting PR binding to chromatin, down regulating cancer stem cell mobilization and blocking immune evasion. ONA-XR is currently being evaluated in four Phase 2 trials and two Phase 0 biomarker pharmacodynamic trials in women with primary or metastatic breast, ovarian, and endometrial cancers. . Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Her2 Negative Metastatic Breast Cancers.
The HER2 Negative Metastatic Breast Cancer pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Negative Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Negative Metastatic Breast Cancer Treatment.
* HER2 Negative Metastatic Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* HER2 Negative Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Negative Metastatic Breast Cancer market.
Get a detailed analysis of the latest innovations in the HER2 Negative Metastatic Breast Cancer pipeline. Explore DelveInsight's expert-driven report today! @ HER2 Negative Metastatic Breast Cancer Unmet Needs [https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HER2 Negative Metastatic Breast Cancer Companies
BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc., AstraZeneca, Dantari, Inc., and others.
Her2 Negative Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
HER2 Negative Metastatic Breast Cancer Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming HER2 Negative Metastatic Breast Cancer Therapies and key HER2 Negative Metastatic Breast Cancer Developments @ HER2 Negative Metastatic Breast Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the HER2 Negative Metastatic Breast Cancer Pipeline Report
* Coverage- Global
* HER2 Negative Metastatic Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* HER2 Negative Metastatic Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* HER2 Negative Metastatic Breast Cancer Companies- BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc., AstraZeneca, Dantari, Inc., and others.
* HER2 Negative Metastatic Breast Cancer Therapies- ADI-PEG 20, DAN-222, Niraparib, Cetuximab, BGB-290 , and others.
Which companies are leading the race in HER2 Negative Metastatic Breast Cancer drug development? Find out in DelveInsight's exclusive HER2 Negative Metastatic Breast Cancer Pipeline Report-access it now! @ HER2 Negative Metastatic Breast Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/her2-negative-metastatic-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Her2 Negative Metastatic Breast Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Her2 Negative Metastatic Breast Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Pamiparib: BeiGene
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Her2 Negative Metastatic Breast Cancer Key Companies
* Her2 Negative Metastatic Breast Cancer Key Products
* Her2 Negative Metastatic Breast Cancer- Unmet Needs
* Her2 Negative Metastatic Breast Cancer- Market Drivers and Barriers
* Her2 Negative Metastatic Breast Cancer- Future Perspectives and Conclusion
* Her2 Negative Metastatic Breast Cancer Analyst Views
* Her2 Negative Metastatic Breast Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2-negative-metastatic-breast-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/wolman-disease-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2 Negative Metastatic Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight here
News-ID: 3877093 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Negative
Negative Net Worth
Negative Net Worth
Negative net worth occurs when your liabilities (debts) exceed your assets (what you own). It's calculated as:
Net Worth = Assets - Liabilities
Example:
Assets: ₹50,000 (house, car, savings)
Liabilities: ₹70,000 (loans, credit card debt)
Net Worth = 50,000 - 70,000 = -20,000
Implications of Negative Net Worth
Financial Instability
Owing more than you own can lead to difficulty meeting obligations like bills and emergencies.
Fewer Investment Opportunities
Limited assets mean fewer chances to grow wealth.
Higher…
How to Remove Negative Google Reviews?
In today's digital age, maintaining a positive online reputation is crucial for businesses of all sizes. Negative Google reviews can significantly impact a company's image, customer trust, and ultimately, its bottom line. Removing these detrimental reviews is not just a matter of reputation management; it's a necessity for sustained business growth. DigitGaps, a market research, analytics, and consulting firm renowned for its premium reports and insights, has conducted an extensive…
The Menace of Negative Inventory in QuickBooks
Kingston, March 13, 2023: Negative inventory is a sign of poor management when processing sales and manufacturing orders, not a necessary occurrence that manufacturers must face. And if you continue to allow the negative stock to generate in your inventory, you will always be risking selling items to customers that you don't have in stock, performing a stock transfer with insufficient inventory and ordering more materials even though necessary materials…
Turning the Negative to Positive - Negative Inventory in QuickBooks
Kingston, November 9, 2022: Negative Inventory does not only occur when sales transactions have been entered without the items on hand.
Negative Inventory can also be a result of failing to enter all purchase orders into QuickBooks and miscalculation of physical inventory. This results in the quantity in QuickBooks being different and the quantity received from a supplier does not match the purchase order in QuickBooks, or if purchase orders…
Negative feedback culture research
Warsaw, Poland, December 15, 2021. - Code Inspiration custom software development and consulting company has completed the research on negative feedback culture.
The core of the research is responses of business professionals from many countries. They provided insightful comments on:
- overall attitude to negative feedback in their companies and countries;
- how getting and sharing negative feedback happens;
- any established procedures on getting and sharing negative feedback;
- any other comments regarding…
Ciniax Negative Erfahrungen [Austria und Germany] Nebenwirkungen!
Gewicht ist für viele ein heikles Thema. Die Menschen beginnen aufgrund ihres Gewichts gestresst zu werden. Aber jeder muss verstehen, dass Gewicht völlig subjektiv ist. Sie sollten nicht von der Meinung anderer betroffen sein. Sie sollten sich wohl in Ihrer Haut fühlen. Aber es bedeutet nicht, dass Sie alle möglichen ungesunden Lebensmittel essen und wie eine Kartoffel lügen müssen und Ihrem Körper alle möglichen Schäden zufügen, indem Sie rechtfertigen, dass…
